News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
復宏漢霖(02696.HK)治療早期乳腺癌注射液臨床試驗申請獲批
復宏漢霖(02696.HK)宣布，公司自主研發的帕妥珠曲妥珠單抗注射液(皮下注射)生物類似藥HLX319的1期臨床試驗申請(INDs)，獲國家藥品監督管理局(NMPA)批准。公司擬於近期條件具備後於中國境內開展相關臨床試驗。據介紹，HLX319是公司自主研發的帕妥珠曲妥珠單抗注射液(皮下注射)生物類似藥，由活性成分曲妥珠單抗、帕妥珠單抗和輔料玻璃酸酶(HLX...
Reset
Send
The window will close in 5 seconds
復宏漢霖(02696.HK)治療早期乳腺癌注射液臨床試驗申請獲批
Close
Recommend
3
Positive
0
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

復宏漢霖(02696.HK)  -1.050 (-1.261%)    Short selling $3.51M; Ratio 10.750%   宣布，公司自主研發的帕妥珠曲妥珠單抗注射液(皮下注射)生物類似藥HLX319的1期臨床試驗申請(INDs)，獲國家藥品監督管理局(NMPA)批准。公司擬於近期條件具備後於中國境內開展相關臨床試驗。

據介紹，HLX319是公司自主研發的帕妥珠曲妥珠單抗注射液(皮下注射)生物類似藥，由活性成分曲妥珠單抗、帕妥珠單抗和輔料玻璃酸酶(HLXTEHAase02，由公司自主研發的新型重組人透明質酸酶)組成，擬用於早期乳腺癌的輔助/新輔助治療與轉移性乳腺癌的治療。(hc/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-14 12:25.)

AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.